No Data
Hong Kong stock concept tracking | The first patient in Shanghai to receive a Brain-computer Interface implant "can now drink water controlled by the brain". There are more clinical trials of domestic Brain-computer Interfaces. (Included concept stocks)
Next year, China will carry out 30 to 50 clinical trial implantation surgeries for domestic Brain-computer Interfaces.
Innovation genes stimulate intrinsic motivation, Xinwei Medical-B (6609.HK) was awarded the 'Annual Innovation Award'.
Innovation is undoubtedly the lifeblood of a company's survival and development. In today's rapidly changing business environment, companies must continuously innovate to maintain competitiveness and achieve self-breakthroughs. As Darwin said, "It is not the strongest species that survive, nor the most intelligent, but the most responsive to change." Therefore, how companies strengthen their core competitiveness, continuously enhance their technology capabilities around innovation, lead industry development, and even promote industrial revolutions will become the key to standing out. Recently, at the "Gelonghui · Global Investment Carnival · 2025" event, Xinwei Medical was awarded the "Annual Innovation Award," highlighting its.
Hong Kong stock concept tracking | Increase in brain-computer interface surgeries, core key technologies expected to be applied and implemented (including concept stocks)
Tsinghua Hongbo: At least 30-50 local brain-computer interface implant surgeries will be conducted next year.
Hong Kong stock concept tracking | Medical devices trade-in program attracts institutional attention, clear trend of market recovery.
"Trade-in" is accelerating in the field of medical devices, and various provinces are intensively issuing "feasibility announcements", "project approval announcements" and "tender procurement notices", injecting a dose of "cardiotonic" into the market.
In the midst of a bustling market, some thoughts on the value potential of Heart Health Medical-B (6609.HK).
The increase once exceeded 80%.
Shanghai HeartCare Medical Technology to Extend Validity Period for A Shares Issue for 12 Months
No Data
